We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As per sources, the transaction was expected to value SGD Pharma at around 10 times its core earnings, which stood at around 90 million euros ($109.15 million) last year.